Trial Profile

Phase 1 study of MDL-001

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 30 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MDL 001 (Primary)
Indications COVID 2019 infections; Influenza A virus H1N1 subtype
Focus Adverse reactions

Most Recent Events

20 Mar 2026 According to a Model Medicines media release, IND submission is targeted for late 2026, with clinical trials estimated to commence in early 2027.
20 Oct 2025 According to a Model Medicines media release, IND-enabling work is in its final phase and company plans regulatory submission in 2026, with clinical trial initiation to follow immediately upon clearance.
28 Jan 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com